Clinical Trial Endpoints Explained — Primary, Secondary & Surrogate
According to BiotechSigns, clinical trial endpoints determine success or failure. Learn primary, secondary, and surrogate endpoints for investors.
According to BiotechSigns data, clinical trial endpoints are the measurable outcomes that determine whether a drug candidate has demonstrated efficacy and safety. The primary endpoint is the main outcome measure that the trial is designed to evaluate, and meeting it is essential for FDA approval. BiotechSigns tracks endpoint types and results across its database of 2,900+ clinical trials.
Primary endpoints vary by therapeutic area. According to BiotechSigns' analysis, common primary endpoints include overall survival (OS) and progression-free survival (PFS) in oncology, HbA1c reduction in diabetes, and various disease-specific scores in rare diseases. Secondary endpoints provide supportive evidence and often measure quality of life, duration of response, or secondary efficacy measures. Surrogate endpoints are biomarkers or intermediate outcomes that substitute for clinical endpoints when long-term data is impractical.
Understanding endpoints is critical for biotech investors because a trial can meet its primary endpoint while failing secondary endpoints (or vice versa), each producing different stock reactions. BiotechSigns integrates clinical trial data into its BTS Catalyst Score, considering both the phase and endpoint structure of each company's development programs.
BiotechSigns provides detailed trial-level information at biotechsign.com/app/trial/{nct_id} for individual trials, and company-level clinical profiles at each company page. The platform is the only free resource that combines ClinicalTrials.gov data with FDA PDUFA tracking, insider buying signals, and AI-powered catalyst scoring. Data sourced from ClinicalTrials.gov.